The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)

Jiaying Yang, Jieyu He, Miao Yu, Taishun Li, Li Luo, Pei LiuMedicine 2016 · DOI

TL;DR

This meta-analysis investigated whether adding molecular targeted agents (MTAs) to standard platinum-gemcitabine (PG) chemotherapy improves outcomes for non-small cell lung cancer (NSCLC). While the combination didn't significantly improve overall survival (OS), it did show benefits in progression-free survival (PFS) and objective response rate (ORR), albeit with an increased risk of certain toxicities.

What Problem Does This Paper Address?

Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related death, often diagnosed at advanced stages where curative surgery isn't an option. First-line treatment typically involves platinum-based chemotherapy, with platinum-gemcitabine (PG) being a common and effective regimen. However, the efficacy of standard chemotherapy has plateaued, necessitating the exploration of novel treatment strategies. Molecular targeted agents (MTAs) have emerged as promising therapies that inhibit specific signaling pathways involved in tumor growth and metastasis. While individual trials combining MTAs with PG have yielded inconsistent results, this meta-analysis aims to consolidate the evidence to determine if this combination offers a survival benefit and a tolerable toxicity profile for unselected NSCLC patients.

Methods

The researchers conducted a systematic review and meta-analysis of published randomized controlled trials (RCTs). They searched major databases (Web of Knowledge, PubMed, Ovid, Embase, Cochrane Library) for studies comparing PG chemotherapy plus an MTA versus PG chemotherapy alone in the first-line treatment of advanced NSCLC. Data extraction focused on overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and common grade 3 or 4 adverse events. Subgroup analyses were performed based on patient race and the type of MTA used. Statistical analysis involved calculating hazard ratios (HR) for OS and PFS, and risk ratios (RR) for ORR and adverse events, using both fixed-effects and random-effects models depending on heterogeneity. Publication bias was assessed using funnel plots and Egger's test.

Datasets

The study analyzed data from 12 first-line RCTs involving a total of 6143 patients. These trials were identified through comprehensive database searches and manual review of conference abstracts. The specific MTAs included in the combination therapies were gefitinib, trastuzumab, erlotinib, cetuximab, bevacizumab, sorafenib, cediranib, and necitumumab.

Key Insights and Ideas

  • PFS and ORR are the primary beneficiaries: The combination therapy significantly improved how long patients lived without their disease progressing (PFS) and how well their tumors responded to treatment (ORR). This suggests MTAs can effectively enhance the anti-tumor activity of PG chemotherapy.
  • OS remains elusive: Despite improvements in PFS and ORR, the combination did not translate into a statistically significant improvement in overall survival. This highlights the complexity of NSCLC treatment and the need for further research into factors influencing long-term survival.
  • Toxicity is a trade-off: The addition of MTAs to PG chemotherapy led to a higher incidence of grade 3 or higher adverse events, particularly rash, anemia, diarrhea, and anorexia, especially when EGFR inhibitors were used. This underscores the importance of careful patient selection and toxicity management.
  • Ethnicity matters: Subgroup analyses revealed that ethnicity can significantly influence treatment outcomes and toxicity. Asian patients, for instance, showed a more pronounced PFS benefit with EGFR inhibitors compared to Caucasian patients, suggesting potential differences in drug response and mutation prevalence.

Key Results

  • PFS: The combination of PG plus MTA significantly improved PFS (HR=0.77, 95% CI=0.66–0.89).
  • ORR: The objective response rate was also significantly higher in the combination group (RR=1.33, 95% CI=1.11–1.60).
  • OS: No significant improvement in overall survival was observed (HR=0.96, 95% CI=0.90–1.01).
  • Toxicities: Increased risks of grade 3 or 4 rash (RR=9.75), anemia (RR=1.21), diarrhea (RR=3.23), and anorexia (RR=1.74) were observed with the combination therapy. Specific MTAs like EGFR inhibitors were associated with higher rates of rash, anemia, diarrhea, and anorexia, while BRAF inhibitors were linked to increased risks of rash, thrombocytopenia, and hypertension.

Limitations and Future Work

The authors acknowledge several limitations:

  • Lack of individual patient data: The meta-analysis relied on aggregated study data, preventing in-depth analysis of how specific patient characteristics (e.g., histological type, age, specific mutations) influence outcomes.
  • Confounding from subsequent treatments: All included trials were first-line treatments. Patients who progressed on the combination therapy might have received subsequent treatments that could confound OS results.
  • Variations in treatment protocols: Differences in dosage regimens and cycle durations across studies could have introduced variability.
  • Unselected patient populations: Most trials included unselected patients, meaning the impact of specific biomarkers (like EGFR mutations) on treatment response could not be fully assessed.

The authors suggest that future research should focus on identifying predictive markers to target MTA treatment to specific patient subpopulations. Further studies are also needed to clarify the impact on OS and to better understand the complex interplay between ethnicity, MTA type, and treatment outcomes.

Summary updated

Abstract

The combination of PG plus MTA was superior to PG alone in terms of PFS and ORR but not in OS. The combination chemotherapy also showed a higher frequency of grade 3 or higher toxic effects in patients with advanced NSCLC than PG chemotherapy.
BibTeX
@inproceedings{yang2016efficacy,
  author = {Jiaying Yang and Jieyu He and Miao Yu and Taishun Li and Li Luo and Pei Liu},
  title = {{The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)}},
  booktitle = {Medicine},
  year = {2016},
  doi = {10.1097/md.0000000000005599},
}
Figure